<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01469910</url>
  </required_header>
  <id_info>
    <org_study_id>SIM-101</org_study_id>
    <nct_id>NCT01469910</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Simotinib Hydrochloride in Healthy Subjects</brief_title>
  <official_title>Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Simotinib Hydrochloride in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and pharmacokinetics of single ascending
      doses of Simotinib Hydrochloride in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence and severity of adverse events</measure>
    <time_frame>within 7 days following administration of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The maximum plasma concentration (Cmax)</measure>
    <time_frame>0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 16h, 24 h, 36 h, 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to Cmax (tmax)</measure>
    <time_frame>0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 16h, 24 h, 36 h, 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 16h, 24 h, 36 h, 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Terminal half-life (t1/2)</measure>
    <time_frame>0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 16h, 24 h, 36 h, 48 h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Simotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simotinib Hydrochloride</intervention_name>
    <description>Single ascending doses: 25 mg、50 mg、100 mg、150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg</description>
    <arm_group_label>Simotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single ascending doses: 150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy , male or female subjects

          -  Age of 18 to 45 years

          -  Body Mass Index (BMI) of 19 to 24 kg/m2; and a total body weight &gt; 50 kg for male, &gt;
             45 kg for female

          -  Written informed consent signed and dated by the subject

          -  Subjects who are willing and able to comply with study procedures

        Exclusion Criteria:

          -  Any clinically significant disease or surgery within 4 weeks prior to the beginning of
             the study

          -  Known hypersensitivity to the study drug or similar drugs

          -  History of any serious disease, including but not limited to circulatory system,
             endocrine system, central nervous system, hematology, immunology, metabolic diseases
             and psychiatric disorders

          -  History of gastrointestinal, hepatic, and renal diseases, affecting drug absorption
             and metabolism

          -  Any clinically significant abnormal clinical laboratory tests

          -  Abnormal ECG or vital signs

          -  A positive test for HIV antibody

          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
             result

          -  History of alcohol consumption within six months of the study defined as: an average
             weekly intake of &gt; 14 units

          -  History of regular tobacco use or nicotine containing products within three months
             prior to screening

          -  Consumption of too much tea or coffee (&gt; 8 cups/day)

          -  Use of any drug, which inhibits or induces hepatic drug metabolism, within 30 days
             prior to the beginning of the study

          -  Use of any drug within 14 days prior to the beginning of the study

          -  Participate in other clinical trials within 30 days prior to the beginning of the
             study

          -  Blood donation within 30 days of dosing

          -  All female subjects must not be of child-bearing potential

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zeneng Cheng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2011</study_first_submitted>
  <study_first_submitted_qc>November 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2011</study_first_posted>
  <last_update_submitted>July 9, 2012</last_update_submitted>
  <last_update_submitted_qc>July 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

